

# The Monitoring & Evaluation/Accountability Framework for the Global Vaccine Action Plan

## 1: Overview

---

### *Background*

The development of a Monitoring and Evaluation/Accountability (M&E/A) Framework is considered to be a critically important element of [the Global Vaccine Action Plan](#) (GVAP). Recognizing the importance to closely monitor the GVAP implementation progress, the [World Health Assembly \(WHA\) resolution](#) called for annual reports on progress at each Regional Committee meeting and at the WHA, through the Executive Board (EB).

In defining the scope of the M&E/A Framework, the GVAP refers to the need:

- to finalize a complete set of GVAP indicators with the appropriate methodology and data sources for each indicator defined and baselines established, where required.
- to invest in improving data quality and developing more robust in-country monitoring and evaluation systems (GVAP WHA 2012 report, paragraph 102).
- to secure commitments aligned with the GVAP from different stakeholders, including countries, civil society organizations, multilateral agencies, private foundations, development partners, and vaccine manufacturers.
- to develop a mechanism for coordinating the implementation of these commitments at global, regional and national levels (GVAP WHA report, paragraph 103).
- to ensure annual reporting of progress at each Regional Committee meeting and at the WHA, through the Executive Board (EB).

### *The Accountability Framework for the U.N. Secretary General's Global Strategy for Women's and Children's Health*

The GVAP calls for leveraging the recommendations of the [Commission for Information and Accountability for Women's and Children's Health](#) and aligning work, wherever possible, with other accountability efforts (GVAP WHA report, paragraph 31).

The Accountability Framework of the [UN Secretary General's Global Strategy for Women's and Children's Health](#) refers to a cyclical process of monitoring, review and remedy/action to assess progress, document success, identify problems that need to be rectified and take prompt action as and where needed. This process needs to occur at the country, regional and global levels as illustrated in Figure 1.<sup>1</sup>


The Commission on Accountability for Women's and Children's Health report is included in the list of documents on the SAGE meeting website. The framework is structured around the 10 recommendations made by the Commission that are categorized under the following headings: (1) better information for better results; (2) better tracking of

---

<sup>1</sup> Commission on Information and Accountability for Women's and Children's Health. Keeping Promises, Measuring Results. World Health Organization 2011 ([http://www.who.int/woman\\_child\\_accountability/en/](http://www.who.int/woman_child_accountability/en/))

resources for women's and children's health; and (3) better oversight of results and resources.

**Figure 1:** The Accountability Framework for the UN Secretary General's Global Strategy for Women's and Children's Health



1. Better information for better health results: aims to collect data on progress against the 11 indicators for maternal, neonatal and child health. It also aims to lead to improvements in collection and reporting of data on vital events and on the enhanced use of information and communications technology in national health information systems.
2. Better resource tracking: involves tracking on total health expenditures and expenditures for women's and children's health by source of funds, while also improving capacity in countries to regularly review health spending and relate them to commitments, gender and other equity goals and results.
3. Better oversight of results and resources: at the global level involved the establishment of an independent Expert Review Group (iERG)<sup>2</sup> that reports annually to the UN Secretary General on the results and resources related to the Global Strategy and on progress in implementation of the Commission's recommendations.


#### *Proposed Process for the GVAP Monitoring & Evaluation / Accountability Framework*

<sup>2</sup> iERG members [http://www.who.int/woman\\_child\\_accountability/iERG/members/en/](http://www.who.int/woman_child_accountability/iERG/members/en/)

A similar cyclical process of monitoring, review, and recommendations for action is proposed for the GVAP M&E/A Framework. In addition to the national and global levels, another level of GVAP M&EA at the regional level is required to accommodate the requirement of reporting annually to the WHO Regional Committees.

Using a similar framework allows for complementarity with the accountability process for the UNSG Global Strategy for Women's and Children's Health and provides opportunities to leverage and/or use these processes for tracking and reporting on some of the aspects of GVAP. This applies in particular to the process to monitor commitments and resources as described in the related documents for this session. Figure 2 illustrates the proposed GVAP M&E/A Framework process. The draft guidelines to make immunization commitments under the UNSG Global Strategy for Women's and Children's Health framework are described in an accompanying document related to this session (Monitoring and Evaluation /Accountability Framework for the Global Vaccine Action Plan – 4: Draft Guidelines for Making Commitments).

**Figure 2:** Proposed GVAP Monitoring and Evaluation/Accountability Framework



The GVAP M&E/A framework will monitor: (1) results (defined as progress against the GVAP goals and Strategic Objectives indicators); (2) document and monitor stakeholder commitments to GVAP; and (3) track resources invested in vaccines and immunization.

The regional and global level review process will utilize existing WHO processes. At the **global level** the review process will be through SAGE to the EB and WHA. The proposed mechanism for the review and reporting at the global level is through the

constitution of a SAGE Decade of Vaccines (DoV) Working Group and is described in an accompanying document related to this session.

At the **regional level**, the WHO Regional Offices are considering the mechanisms for review and reporting to the Regional Committees. Member States would need to consider the review and reporting modalities at the country level. It is envisaged that countries will develop a national level M&E/A framework to monitor performance of the programme and a review process to document best practices, identify problems and make recommendations for corrective action. At the **country level**, the National Immunization Technical Advisory Groups (NITAGs) and the Interagency Coordination Committees (ICCs) may have important roles to play in this regard.

For the R&D indicators, it is proposed that the Global Vaccine Research Forum (GVRF) be used to review progress and identify priority areas approximately every two years. Accordingly, **progress reports for the R&D indicators will be made every two years.**

*Issues for SAGE consideration:*

1. *Feedback on the proposed structure of the GVAP M&E/Accountability Framework.*
2. *Comments on the reporting process, taking note of the fact that the reports reviewed by SAGE will contain data on monitoring indicators for the previous year, but the same report presented to the EB and WHA will have data from two years previous (e.g. EB and WHA report of 2015 will have country level data from 2013).*